Jeffry Simko
Overview
Explore the profile of Jeffry Simko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
536
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu S, Hawley S, Kunder C, Hsu E, Shen M, Westphalen L, et al.
Sci Rep
. 2024 Jan;
14(1):486.
PMID: 38177207
Distinguishing indolent from clinically significant localized prostate cancer is a major clinical challenge and influences clinical decision-making between treatment and active surveillance. The development of novel predictive biomarkers will help...
2.
Baraban E, Ding C, White M, Vohra P, Simko J, Boyle K, et al.
Am J Surg Pathol
. 2022 Aug;
46(12):1650-1658.
PMID: 36006769
Male-to-female (MtF) transgender individuals are at risk for prostate cancer, although guidelines for screening and management in this population are not well established. We describe a series of 9 MtF...
3.
Friedlander T, Welty C, Anantharaman A, Schonhoft J, Jendrisak A, Lee J, et al.
J Urol
. 2019 Jun;
202(4):732-741.
PMID: 31216253
Purpose: Approximately 15% of men with newly diagnosed prostate cancer have high risk features which increase the risk of recurrence and metastasis. Better predictive biomarkers could allow for earlier detection...
4.
Hagihara K, Chan S, Zhang L, Oh D, Wei X, Simko J, et al.
Oncoimmunology
. 2018 Dec;
8(1):e1486953.
PMID: 30546940
Sipuleucel-T is the only FDA-approved immunotherapy for metastatic castration-resistant prostate cancer. The mechanism by which this treatment improves survival is not fully understood. We have previously shown that this treatment...
5.
Leapman M, Nguyen H, Cowan J, Xue L, Stohr B, Simko J, et al.
Eur Urol
. 2018 Sep;
74(5):668-675.
PMID: 30181067
Background: Despite the availability of numerous genomic predictors of prostate cancer (PCa) outcome, few comparative studies have been performed. Objective: To compare the prognostic utility of previously validated immunohistochemical (IHC)...
6.
Lelo A, Prip F, Harris B, Solomon D, Berry D, Chaldekas K, et al.
Clin Cancer Res
. 2018 Jun;
24(17):4145-4153.
PMID: 29954776
Most bladder cancers are early-stage tumors known as papillary non-muscle-invasive bladder cancer (NMIBC). After resection, up to 70% of NMIBCs recur locally, and up to 20% of these recurrences progress...
7.
Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes
Leapman M, Cowan J, Simko J, Roberge G, Stohr B, Carroll P, et al.
Eur Urol
. 2016 Dec;
71(5):750-759.
PMID: 27940155
Background: There is growing enthusiasm for the adoption of a novel grade grouping system to better represent Gleason scores. Objective: To evaluate the ability of prognostic Gleason grade groups to...
8.
Li Y, Mongan J, Behr S, Sud S, Coakley F, Simko J, et al.
Radiographics
. 2016 Jun;
36(4):1055-75.
PMID: 27315446
Recent advances in magnetic resonance (MR) imaging of the prostate gland have dramatically improved the ability to detect and stage adenocarcinoma of the prostate, one of the most frequently diagnosed...
9.
Nordstrom T, Van Blarigan E, Ngo V, Roy R, Weinberg V, Song X, et al.
Prostate
. 2015 Nov;
76(4):339-48.
PMID: 26585352
Background: Carotenoids are a class of nutrients with antioxidant properties that have been purported to protect against cancer. However, the reported associations between carotenoids and prostate cancer have been heterogeneous...
10.
Newcomb L, Thompson Jr I, Boyer H, Brooks J, Carroll P, Cooperberg M, et al.
J Urol
. 2015 Sep;
195(2):313-20.
PMID: 26327354
Purpose: Active surveillance represents a strategy to address the overtreatment of prostate cancer, yet uncertainty regarding individual patient outcomes remains a concern. We evaluated outcomes in a prospective multicenter study...